Urolithin A: What Human Trials Show — Mostly Funded by the Seller

By Erin Rose · Updated July 18, 2026 · Methodology

Educational overview — not medical advice. No human trial has tested urolithin A for lifespan extension, anti-aging, or disease prevention at any dose. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

As an Amazon Associate we earn from qualifying purchases. On best urolithin A, there is no clean trial-matched pick — we say so explicitly and explain each option's specific flaw.

Start here

What urolithin A is, and the honest funding count

Urolithin A is a metabolite the gut produces from ellagitannins — compounds found in foods like pomegranates, walnuts, and some berries. It's not an essential nutrient in the vitamin sense: there's no deficiency state, no RDA, and no government-set upper limit, so any claimed benefit of supplementing has to stand entirely on its own trial evidence, not on "correcting a shortfall." What makes urolithin A genuinely different from most compounds in this content category is that most people are unreliable natural producers of it — only around 40% of adults reliably convert dietary ellagitannins into meaningful urolithin A levels, and direct supplementation bypasses that gut-bacteria variability with far more consistent plasma exposure (Singh 2021). That's a real, non-marketing biological rationale for supplementing directly — though it's a mechanistic finding, not proof of a clinical benefit on its own.

On the clinical side, 7 human RCTs have tested urolithin A, spanning sedentary older adults, untrained middle-aged adults, trained young athletes, elite distance runners, and adolescent soccer players. A muscle-endurance and, in some populations, strength signal shows up repeatedly — genuinely more replication across independent populations than most longevity-marketed ingredients can claim. But read the funding roster before the results: 5 of the 7 trials are Amazentis-funded and/or co-authored by Amazentis employees or executives (Andreux 2019, Singh 2021, Liu 2022 partially, Singh 2022 fully, Whitfield 2025). Only Zhao 2024 — Jiangsu Province educational grant, explicit no-conflict-of-interest disclosure — is fully independent, and it points the same direction on endurance, which is reassuring. But it's one trial, not a replication at scale by unrelated labs. A seventh trial (Monsalve Acevedo 2025, an adolescent soccer pilot) has partial industry-adjacent funding — one author received travel reimbursement from the Mitopure manufacturer, though the primary grant was unrelated.

Does it work? (the honest short version)

Unevenly positive, and read the funding disclosure before the results. Singh 2022 — the single strongest positive trial in this pack, and also fully Amazentis-funded, with every author a current or former Amazentis employee, board member, or scientific advisor — found hamstring strength improved about 12% at both 500mg and 1,000mg doses. Two of the industry-funded trials, Liu 2022 (older adults) and Whitfield 2025 (elite runners), had null primary endpoints — 6-minute walk distance and 3000m time-trial performance, respectively — with the positive findings landing on secondary measures like muscle-endurance fatigue resistance and VO2max. Naming the null primary before the positive secondary is the honest way to read both. Zhao 2024, the one independent trial, found functional endurance (reps-to-failure) improved in young trained athletes, though maximal strength (1RM) did not. See the full population-by-population breakdown on the muscle & endurance page and the full funding-roster analysis on does it work.

The buying problem: the trial-grade product isn't reliably on Amazon

This is the finding that separates urolithin A from most of the ingredients on this site: the Amazentis-funded trials (5 of the 7 in this evidence base) used Mitopure-branded urolithin A at 500-1,000mg/day depending on the trial, and Timeline sells Mitopure direct-to-consumer — it does not have a reliable, stable Amazon buy-box listing. Whether the independently-funded trials (Zhao 2024, the soccer pilot) used the same branded material isn't established in this evidence base. That leaves two realistic Amazon options, and neither is a clean trial match. Pure Encapsulations Renual carries the Mitopure brand (the correct molecule, free urolithin A) but at only 250mg per serving — half the lowest dose (500mg) shown to improve strength — bundled with resveratrol and CoQ10, which dilutes the cost-per-mg of the actual studied ingredient. Nutri's urolithin A diacetate product hits the 1,000mg trial-matched dose, but diacetate is an ester/prodrug form — a different molecule than the free urolithin A tested in every trial — and dose-equivalence between the two should not be assumed. See the full honest comparison, including why we didn't force a fake "winner," on best urolithin A.

On safety: no serious adverse events have been reported across any trial in this pack, at doses up to 2,000mg as a single dose or 1,000mg/day sustained for 4 months (Andreux 2019, Singh 2022, Liu 2022, Whitfield 2025) — a genuinely reassuring safety record relative to most compounds in this category. But that still tops out at 4 months of continuous human dosing; there is no 6-month-plus or multi-year human safety data at any dose, and no pregnancy or breastfeeding data exists. See the full dose-by-dose breakdown on the dosage guide.

Frequently asked questions

Related guides

• NMN — another longevity-marketed ingredient where a rigorous meta-analysis found a null result the marketing skips past
• Nicotinamide Riboside — NAD+ reliably rises, but independent functional trials mostly came back null or underpowered
• Spermidine — the confirmatory human trial built to prove a benefit and didn't, on its primary endpoint
• CoQ10 — another mitochondrial-energy-adjacent supplement with its own absorption-form distinction

Sources